Kodiak Sciences Stock Surges After Strong Phase 3 Eye Drug Results
Kodiak Sciences shares surged after Zenkuda hit its primary endpoint in the GLOW2 Phase 3 study for diabetic retinopathy.
/ 3 items
#KOD↓
JPMorgan Upgrades Kodiak Sciences on KSI-101 Potential
JPMorgan raises Kodiak Sciences rating to Overweight with $24 price target, citing reduced risk for KSI-101 drug treating eye inflammation and swelling.
Kodiak Sciences Gets 'Buy' Rating: What Investors Need to Know
Kodiak gets a "Buy" rating and $15 target. Final results for its 3 eye drugs are due 2026. Watch for rival Roche's data soon.